Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.96 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.96 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL14109970 | 1.00 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29846325 | 1.00 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL40902 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL31298106 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL6238952 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29461927 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29245643 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8378216 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7532547 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL1314201 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007022609-A1 | PHARMACEUTICAL COMPOSITION OF MORPHINE IN READY-TO-USE INJECTABLE SOLUTION FORM AND SINGLE DOSAGE FORM OF MORPHINE FOR EPIDURAL OR INTRATHECAL ADMINISTRATION | Cristália Produtos Químicos Farmacêuticos Ltda. (BR) | 2007-03-01 | — | — | WO | claimed |
| US-20220362279-A1 | USE OF OLIGONUCLEOTIDES FOR THE TREATMENT AND PREVENTION OF PAIN | CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (AR) | 2022-11-17 | — | — | US | disclosed |
| US-10195139-B2 | Preparation for transnasal application | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10160719-B2 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2018-12-25 | — | — | US | disclosed |
| EP-2116264-B1 | PREPARATION FOR TRANSNASAL APPLICATION | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2017-05-18 | — | — | US | disclosed |
| WO-2015089530-A1 | EXTENDED-RELEASE ORAL DOSAGE FORM CONTAINING MORPHINE AND NALOXONE | G.L. PHARMA GmbH (AT) | 2015-06-25 | — | — | WO | disclosed |
| CN-101668544-B | Preparation for transnasal application | SHIN NIPPON BIOMEDICAL LAB LTD | 2013-04-24 | — | — | CN | disclosed |
| US-20130095145-A1 | Preparation for Transnasal Application | NAGATA RYOICHI (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8337817-B2 | Preparation for transnasal application | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| CN-1561203-A | Pharmaceutically acceptable salts | GRUENENTHAL GMBH (DE) | 2005-01-05 | — | — | CN | disclosed |
| EP-1390023-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030219494-A1 | Compositions and methods of using them | QUEENSLAND, UNIVERSITY OF (AU) | 2003-11-27 | — | — | US | disclosed |
| EP-0900076-B1 | TRANSDERMAL DEVICE | SVEDMAN PAUL (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002067916-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002067651-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | disclosed |
| US-20020044966-A1 | Pharmaceutical formulations containing an opioid and an alpha-agonist | GRUENENTHAL GMBH (DE) | 2002-04-18 | — | — | US | disclosed |
| EP-0900076-A1 | TRANSDERMAL DEVICE | Svedman, Pal (CH) | 1999-03-10 | — | — | EP | disclosed |
| EP-0865789-A2 | Pharmaceutical compositions for intranasal administration of dihydroergotamine | Merkus, Franciscus Wilhelmus Henricus Maria (BE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997034587-A2 | TRANSDERMAL DEVICE | SVEDMAN PAUL (CH) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219494-A1 | Compositions and methods of using them | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
| US-10160719-B2 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | OPRM1 2283/4885OPRD1 2343/4885OPRK1 1831/4885 |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | SLC5A1, SLC5A2, SLC35A1 | OPRM1 2283/4885OPRD1 2343/4885OPRK1 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.